Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

baxter healthcare ltd - desflurane - inhalation vapour - 1ml/1ml

Bandaríkin - enska - NLM (National Library of Medicine)

baxter healthcare corporation - desflurane (unii: crs35bz94q) (desflurane - unii:crs35bz94q) - desflurane 240 ml in 240 ml - suprane is indicated as an inhalation agent for induction of anesthesia for inpatient and outpatient surgery in adults. suprane is contraindicated as an inhalation agent for the induction of anesthesia in pediatric patients because of a high incidence of moderate to severe upper airway adverse events. suprane is indicated as an inhalation agent for maintenance of anesthesia for inpatient and outpatient surgery in adults and in pediatric patients. after induction of anesthesia with agents other than suprane, and tracheal intubation, suprane is indicated for maintenance of anesthesia in infants and children. suprane is not approved for maintenance of anesthesia in non-intubated children due to an increased incidence of respiratory adverse reactions, including coughing, laryngospasm, and secretions [see warnings and precautions (5.3) and clinical studies (14.5) ]. the use of suprane is contraindicated in the following conditions: risk summary there are no adequate and well-controlled studies in pregnant women

Ísrael - enska - Ministry of Health

baxter healthcare distribution ltd., israel - desflurane - solution for inhalation - desflurane 100 % - desflurane - desflurane - sulorane is indicated as an inhalation agent for induction and/or maintenance of anesthesia in adults and maintenance of anesthesia in infants and children.

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

baxter healthcare ltd - desflurane - inhalation vapour - 1ml/1ml

Bandaríkin - enska - NLM (National Library of Medicine)

henry schein, inc. - desflurane (unii: crs35bz94q) (desflurane - unii:crs35bz94q) - 1.1 induction of anesthesia suprane is indicated as an inhalation agent for induction of anesthesia for inpatient and outpatient surgery in adults. suprane is contraindicated as an inhalation agent for the induction of anesthesia in pediatric patients because of a high incidence of moderate to severe upper airway adverse events. 1.2 maintenance of anesthesia suprane is indicated as an inhalation agent for maintenance of anesthesia for inpatient and outpatient surgery in adults and in pediatric patients. after induction of anesthesia with agents other than suprane, and tracheal intubation, suprane is indicated for maintenance of anesthesia in infants and children. suprane is not approved for maintenance of anesthesia in non-intubated children due to an increased incidence of respiratory adverse reactions, including coughing, laryngospasm, and secretions [see warnings and precautions (5.3) and clinical studies (14.5)]. suprane (desflurane, usp) is indicated as an inhalation agent for induction of anesthesia f

Írland - enska - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - desflurane - inhalation vapour, solution - 100 percent volume/volume - halogenated hydrocarbons; desflurane

Írland - enska - HPRA (Health Products Regulatory Authority)

baxter holding b.v. - desflurane - inhalation vapour, solution - 100 percent volume/volume - halogenated hydrocarbons; desflurane

Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

baxter sa-nv - desflurane 100 % v/v - inhalation vapour, liquid - 100 % - desflurane 1000 mg/g - desflurane

Kanada - enska - Health Canada

baxter corporation - desflurane - liquid - 100% - desflurane 100% - inhalation anesthetics

Bandaríkin - enska - NLM (National Library of Medicine)

baxter healthcare corporation - desflurane (unii: crs35bz94q) (desflurane - unii:crs35bz94q) - suprane is indicated as an inhalation agent for induction of anesthesia for inpatient and outpatient surgery in adults. suprane is contraindicated as an inhalation agent for the induction of anesthesia in pediatric patients because of a high incidence of moderate to severe upper airway adverse events. suprane is indicated as an inhalation agent for maintenance of anesthesia for inpatient and outpatient surgery in adults and in pediatric patients. after induction of anesthesia with agents other than suprane, and tracheal intubation, suprane is indicated for maintenance of anesthesia in infants and children. suprane is not approved for maintenance of anesthesia in non-intubated children due to an increased incidence of respiratory adverse reactions, including coughing, laryngospasm, and secretions [see warnings and precautions (5.3) and clinical studies (14.5) ]. the use of suprane is contraindicated in the following conditions: risk summary there are no adequate and well-controlled studies in pregnant women.